Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes

被引：93

作者：

Singh, Mallika ^{[1
]}

Murriel, Christopher L. ^{[1
]}

Johnson, Leisa ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

来源：

CANCER RESEARCH | 2012年 / 72卷 / 11期

关键词：

GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; HUMAN TUMOR XENOGRAFTS; PANCREATIC-CANCER; PATHWAY ACTIVATION; PLUS GEMCITABINE; CLINICAL-TRIALS; KRAS; CHEMOTHERAPY; EXPRESSION;

D O I：

10.1158/0008-5472.CAN-11-2786

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The high failure rate of late-stage human clinical trials, particularly in oncology, predicates the need for improved translation of preclinical data from mouse tumor models into clinical predictions. Genetically engineered mouse models (GEMM) may fulfill this need, because they mimic spontaneous and autochthonous disease progression. Using oncogenic Kras-driven GEMMs of lung and pancreatic adenocarcinoma, we recently showed that these models can closely phenocopy human therapeutic responses to standard-of-care treatment regimens. Here we review the successful preclinical application of such GEMMs, as well as the potential for discovering predictive biomarkers and gaining mechanistic insights into clinical outcomes and drug resistance in human cancers. Cancer Res; 72(11); 2695-700. (C)2012 AACR.

引用

页码：2695 / 2700

页数：6

共 47 条

[41] Cancer Modeling in the modern era: Progress and challenges [J].

Van Dyke, T ;

Jacks, T .

CELL, 2002, 108 (02) :135-144

[42] Guidelines for the welfare and use of animals in cancer research [J].

Workman, P. ;

Aboagye, E. O. ;

Balkwill, F. ;

Balmain, A. ;

Bruder, G. ;

Chaplin, D. J. ;

Double, J. A. ;

Everitt, J. ;

Farningham, D. A. H. ;

Glennie, M. J. ;

Kelland, L. R. ;

Robinson, V. ;

Stratford, I. J. ;

Tozer, G. M. ;

Watson, S. ;

Wedge, S. R. ;

Eccles, S. A. ;

Navaratnam, V. ;

Ryder, S. .

BRITISH JOURNAL OF CANCER, 2010, 102 (11) :1555-1577

[43] Phosphatidylinositol 3-Kinase Mediates Bronchioalveolar Stem Cell Expansion in Mouse Models of Oncogenic K-ras-Induced Lung Cancer [J].

Yang, Yanan ;

Iwanaga, Kentaro ;

Raso, Maria Gabriela ;

Wislez, Marie ;

Hanna, Amy E. ;

Wieder, Eric D. ;

Molldrem, Jeffrey J. ;

Wistuba, Ignacio I. ;

Powis, Garth ;

Demayo, Francesco J. ;

Kim, Carla F. ;

Kurie, Jonathan M. .

PLOS ONE, 2008, 3 (05)

[44] A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras [J].

Yang, Yanan ;

Wislez, Marie ;

Fujimoto, Nobukazu ;

Prudkin, Ludmila ;

Izzo, Julie G. ;

Uno, Futoshi ;

Ji, Lin ;

Hanna, Amy E. ;

Langley, Robert R. ;

Liu, Diane ;

Johnson, Faye M. ;

Wistuba, Ignacio ;

Kurie, Jonathan M. .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (04) :952-960

[45] Envisioning the future of early anticancer drug development [J].

Yap, Timothy A. ;

Sandhu, Shahneen K. ;

Workman, Paul ;

de Bono, Johann S. .

NATURE REVIEWS CANCER, 2010, 10 (07) :514-U25

[46] Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas [J].

Zhou, Yinghui ;

Rideout, William M., III ;

Zi, Tong ;

Bressel, Angela ;

Reddypalli, Shailaja ;

Rancourt, Rebecca ;

Woo, Jin-Kyeung ;

Horner, James W. ;

Chin, Lynda ;

Chiu, M. Isabel ;

Bosenberg, Marcus ;

Jacks, Tyler ;

Clark, Steven C. ;

DePinho, Ronald A. ;

Robinson, Murray O. ;

Heyer, Joerg .

NATURE BIOTECHNOLOGY, 2010, 28 (01) :71-U102

[47] Mouse models of human AML accurately predict chemotherapy response [J].

Zuber, Johannes ;

Radtke, Ina ;

Pardee, Timothy S. ;

Zhao, Zhen ;

Rappaport, Amy R. ;

Luo, Weijun ;

McCurrach, Mila E. ;

Yang, Miao-Miao ;

Dolan, M. Eileen ;

Kogan, Scott C. ;

Downing, James R. ;

Lowe, Scott W. .

GENES & DEVELOPMENT, 2009, 23 (07) :877-889

← 1 2 3 4 5 →